Back to Journals » Biologics: Targets and Therapy » Volume 6
Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir
Authors D'Ambrosio, Aghemo A, Colombo M
Received 17 April 2012
Accepted for publication 11 May 2012
Published 18 October 2012 Volume 2012:6 Pages 363—370
DOI https://doi.org/10.2147/BTT.S20673
Review by Single anonymous peer review
Peer reviewer comments 3
Roberta D’Ambrosio, Alessio Aghemo, Massimo Colombo
Centro A.M. e A. Migliavacca, First Division of Gastroenterology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy
Abstract: Telaprevir (TVR) is an orally available protease inhibitor of the hepatitis C virus that in association with pegylated interferon and ribavirin (PR) was shown to improve the rates of sustained virological response and potentially reduce treatment duration in adult patients with chronic hepatitis C genotype. Despite its robust activity in both treatment-naïve and experienced patients, the addition of TVR to PR is counterbalanced by increased costs and adverse events; moreover, there are still areas of uncertainty that regard treatment of patients with advanced liver disease, the role of patient stratification by genetic predictors, and the use/need for a lead-in phase with PR. Since TVR regimens have been associated with the risk of viral mutants that may cause treatment failure and jeopardize future therapeutic strategies with direct-acting antiviral agents, early stopping rules have been designed to protect patients with a poor virological response to TVR regimens against such a risk.
Keywords: protease inhibitor, pegylated interferon, ribavirin
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.